T Cell Therapy of Opportunistic Cytomegalovirus Infection

NCT02982902

Status	RECRUITING
Phase	Early Phase 1
Sponsor	Mari Dallas
Enrollment	20 participants

Key Eligibility Criteria

Inclusion (11)

- Patients must have received allogeneic hematopoietic stem cell transplant and be greater than 30 days post-transplant at the time of registration
- Patients must have documented opportunistic CMV infection, or reactivation; the criteria include (both of the following criteria must be met)
- Patients may have asymptomatic viremia (\>1000 copies/ml) OR presence of symptoms secondary to CMV infection, AND
- Patients must have ONE OF THE NEXT FOUR CRITERIA:
- Absence of an improvement of viral load after e 14 days of antiviral therapy with ganciclovir, valganciclovir or foscarnet (decrease by at least 1 log, i.e. 10-fold) or

... and 6 more (see full listing online)

Exclusion (11)

- Pregnant or breastfeeding women are excluded from this study.
- Patients with opportunistic viral infections other than CMV.
- Patients with active, grade 2-4, acute graft vs. host disease (GVHD), chronic GVHD or any condition requiring high doses of glucocorticosteroid (\>0.5 mg/kg/day prednisone or its equivalent) as treatment
- Treatment with antithymocyte globulin within 28 days of planned infusion of virus - specific, antigen selected T cells.
- Treatment with virus - specific T cells within 6 weeks (42 days) of planned infusion.

... and 6 more (see full listing online)

Locations (1 total)

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States